Revisions for 188Re-marked Ior C5 MAb in persistent or relapsing ovary epithelial cancer, phase I. | Registro Público Cubano de Ensayos Clínicos

The revisions let you track differences between multiple versions of a post.

To edit, publish or delete one of the revisions below, click on its saved date.

Published clinical_trials 188Re-marked Ior C5 MAb in persistent or relapsing ovary epithelial cancer, phase I. has only one revision